VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 127 filers reported holding VAXCYTE INC in Q3 2022. The put-call ratio across all filers is 0.98 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,643,185 | +7.1% | 130,310 | +4.9% | 0.01% | +14.3% |
| Q2 2023 | $6,201,499 | +173757.6% | 124,179 | +30.5% | 0.01% | +75.0% |
| Q1 2023 | $3,567 | -19.0% | 95,174 | +3.7% | 0.00% | -33.3% |
| Q4 2022 | $4,402 | -99.7% | 91,797 | +34.5% | 0.01% | +200.0% |
| Q3 2022 | $1,638,000 | +22.3% | 68,230 | +10.9% | 0.00% | 0.0% |
| Q2 2022 | $1,339,000 | +9.1% | 61,548 | +21.2% | 0.00% | 0.0% |
| Q1 2022 | $1,227,000 | +9.8% | 50,789 | +8.2% | 0.00% | +100.0% |
| Q4 2021 | $1,117,000 | -7.2% | 46,937 | -1.1% | 0.00% | -50.0% |
| Q3 2021 | $1,204,000 | +17.9% | 47,473 | +4.7% | 0.00% | +100.0% |
| Q2 2021 | $1,021,000 | +80.7% | 45,346 | +58.6% | 0.00% | 0.0% |
| Q1 2021 | $565,000 | -5.0% | 28,583 | +27.6% | 0.00% | 0.0% |
| Q4 2020 | $595,000 | -40.9% | 22,397 | +9.8% | 0.00% | -50.0% |
| Q3 2020 | $1,007,000 | – | 20,401 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |